Table of Contents Author Guidelines Submit a Manuscript
International Journal of Medicinal Chemistry
Volume 2011, Article ID 480652, 15 pages
http://dx.doi.org/10.1155/2011/480652
Review Article

Pyrazolo Derivatives as Potent Adenosine Receptor Antagonists: An Overview on the Structure-Activity Relationships

1Department of Pharmacy, National University of Singapore, 3 Science Drive 2, Singapore 117543
2Dipartimento di Scienze Farmaceutiche, Università degli Studi di Trieste, Piazzale Europa 1, 34127 Trieste, Italy

Received 2 November 2010; Accepted 10 February 2011

Academic Editor: Rosaria Volpini

Copyright © 2011 Siew Lee Cheong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. A. Jacobson and Z. G. Gao, “Adenosine receptors as therapeutic targets,” Nature Reviews Drug Discovery, vol. 5, no. 3, pp. 247–264, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Moro, Z. G. Gao, K. A. Jacobson, and G. Spalluto, “Progress in the pursuit of therapeutic adenosine receptor antagonists,” Medicinal Research Reviews, vol. 26, no. 2, pp. 131–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. W. J. Welch, “Adenosine A1 receptor antagonists in the kidney: effects in fluid-retaining disorders,” Current Opinion in Pharmacology, vol. 2, no. 2, pp. 165–170, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. T. V. Dunwiddie and S. A. Masino, “The role and regulation of adenosine in the central nervous system,” Annual Review of Neuroscience, vol. 24, pp. 31–55, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. K. A. Jacobson, “Adenosine A3 receptors: novel ligands and paradoxical effects,” Trends in Pharmacological Sciences, vol. 19, no. 5, pp. 184–191, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Okamura, Y. Kurogi, K. Hashimoto, H. Nishikawa, and Y. Nagao, “Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 10, pp. 2443–2446, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Merighi, P. Mirandola, K. Varani et al., “Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine,” Biochemical Pharmacology, vol. 66, no. 5, pp. 739–748, 2003. View at Publisher · View at Google Scholar
  8. R. Grondin, P. J. Bédard, A. H. Tahar, L. Grégoire, A. Mori, and H. Kase, “Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys,” Neurology, vol. 52, no. 8, pp. 1673–1677, 1999. View at Google Scholar · View at Scopus
  9. P. Jenner, “Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease,” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 729–738, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Feoktistov, I. Biaggioni, R. Polosa, and S. T. Holgate, “Adenosine A2B receptors: a novel therapeutic target in asthma?” Trends in Pharmacological Sciences, vol. 19, no. 4, pp. 148–153, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. S. T. Holgate, “The identification of the adenosine A2B receptor as a novel therapeutic target in asthma,” British Journal of Pharmacology, vol. 145, no. 8, pp. 1009–1015, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Schenone, M. Radi, and M. Botta, “Pyazolopyrimidines: old molecules, new targets,” Targets in Heterocyclic Systems-Chemistry and Properties, vol. 11, pp. 44–69, 2007. View at Google Scholar
  13. F. Gatta, M. R. Del Giudice, A. Borioni, P. A. Borea, S. Dionisotti, and E. Ongini, “Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A2 receptor antagonists,” European Journal of Medicinal Chemistry, vol. 28, no. 7-8, pp. 569–576, 1993. View at Google Scholar · View at Scopus
  14. P. G. Baraldi, S. Manfredini, D. Simoni et al., “Sythesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A2A adenosine receptor antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 4, no. 21, pp. 2539–2544, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. P. G. Baraldi, B. Cacciari, G. Spalluto et al., “Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A2A adenosine antagonists,” Journal of Medicinal Chemistry, vol. 39, no. 5, pp. 1164–1171, 1996. View at Google Scholar · View at Scopus
  16. P. G. Baraldi, B. Cacciari, G. Spalluto et al., “Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists,” Journal of Medicinal Chemistry, vol. 41, no. 12, pp. 2126–2133, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. P. G. Baraldi, B. Cacciari, R. Romagnoli et al., “7-substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility,” Journal of Medicinal Chemistry, vol. 45, no. 1, pp. 115–126, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Dionisotti, S. Ferrara, C. Molta, C. Zocchi, and E. Ongini, “Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [ 3H]SCH 58261,” Journal of Pharmacology and Experimental Therapeutics, vol. 278, no. 3, pp. 1209–1214, 1996. View at Google Scholar · View at Scopus
  19. S. Todde, R. M. Moresco, P. Simonelli et al., “Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A2A receptor system using positron emission tomography,” Journal of Medicinal Chemistry, vol. 43, no. 23, pp. 4359–4362, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Kecskés, T. S. Kumar, L. Yoo, Z. G. Gao, and K. A. Jacobson, “Novel Alexa Fluor-488 labeled antagonist of the A2A adenosine receptor: application to a fluorescence polarization-based receptor binding assay,” Biochemical Pharmacology, vol. 80, no. 4, pp. 506–511, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. P. G. Baraldi, B. Cacciari, R. Romagnoli et al., “Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A3 adenosine receptor antagonists,” Journal of Medicinal Chemistry, vol. 42, no. 22, pp. 4473–4478, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. P. G. Baraldi, B. Cacciari, R. Romagnoli et al., “Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A3 adenosine receptor antagonists: influence of the chain at the N8 pyrazole nitrogen,” Journal of Medicinal Chemistry, vol. 43, no. 25, pp. 4768–4780, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. B. R. Neustadt, J. Hao, N. Lindo et al., “Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 5, pp. 1376–1380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. P. G. Baraldi, B. Cacciari, R. Romagnoli et al., “Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor ligands: a starting point for searching A2B adenosine receptor antagonists,” Drug Development Research, vol. 53, no. 2-3, pp. 225–235, 2001. View at Publisher · View at Google Scholar
  25. G. Pastorin, T. Da Ros, G. Spalluto et al., “Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A3 and A2B adenosine receptor subtypes: a molecular modeling investigation,” Journal of Medicinal Chemistry, vol. 46, no. 20, pp. 4287–4296, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Varani, S. Merighi, S. Gessi et al., “[3H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors,” Molecular Pharmacology, vol. 57, no. 5, pp. 968–975, 2000. View at Google Scholar · View at Scopus
  27. P. G. Baraldi, B. Cacciari, S. Moro et al., “Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A3 adenosine receptor antagonists,” Journal of Medicinal Chemistry, vol. 45, no. 4, pp. 770–780, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Pastorin, T. Da Ros, C. Bolcato et al., “Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations,” Journal of Medicinal Chemistry, vol. 49, no. 5, pp. 1720–1729, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Moro, P. Braiuca, F. Deflorian et al., “Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study,” Journal of Medicinal Chemistry, vol. 48, no. 1, pp. 152–162, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Maconi, G. Pastorin, T. Da Ros et al., “Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A3 adenosine receptor antagonist,” Journal of Medicinal Chemistry, vol. 45, no. 17, pp. 3579–3582, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. P. G. Baraldi, F. Fruttarolo, M. A. Tabrizi et al., “Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists,” Journal of Medicinal Chemistry, vol. 46, no. 7, pp. 1229–1241, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. S. L. Cheong, A. Dolzhenko, S. Kachler et al., “The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA3 adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition,” Journal of Medicinal Chemistry, vol. 53, no. 8, pp. 3361–3375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Okamura, Y. Kurogi, K. Hashimoto et al., “Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 14, pp. 3775–3779, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Colotta, D. Catarzi, F. Varano et al., “1,2,4-triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists,” Journal of Medicinal Chemistry, vol. 43, no. 6, pp. 1158–1164, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Colotta, D. Catarzi, F. Varano et al., “Synthesis and structure-activity relationships of a new set of 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as adenosine receptor antagonists,” Bioorganic and Medicinal Chemistry, vol. 11, no. 16, pp. 3541–3550, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Colotta, D. Catarzi, F. Varano et al., “1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies,” Journal of Medicinal Chemistry, vol. 47, no. 14, pp. 3580–3590, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Lenzi, V. Colotta, D. Catarzi et al., “4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies,” Journal of Medicinal Chemistry, vol. 49, no. 13, pp. 3916–3925, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Colotta, D. Catarzi, F. Varano et al., “Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists,” Bioorganic and Medicinal Chemistry, vol. 16, no. 11, pp. 6086–6102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Colotta, D. Catarzi, F. Varano et al., “Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists,” Journal of Medicinal Chemistry, vol. 43, no. 16, pp. 3118–3124, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. V. Colotta, D. Catarzi, F. Varano et al., “New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies,” Journal of Medicinal Chemistry, vol. 50, no. 17, pp. 4061–4074, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. P. G. Baraldi, M. A. Tabrizi, D. Preti et al., “New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists,” Journal of Medicinal Chemistry, vol. 48, no. 15, pp. 5001–5008, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. O. Lenzi, V. Colotta, D. Catarzi et al., “2-phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human a adenosine receptor antagonists: new insights into the receptor-antagonist recognition,” Journal of Medicinal Chemistry, vol. 52, no. 23, pp. 7640–7652, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. L. P. Davies, S. C. Chow, and J. H. Skerritt, “Pyrazolo[3,4-d]pyrimidines as adenosine antagonists,” Life Sciences, vol. 34, no. 22, pp. 2117–2128, 1984. View at Publisher · View at Google Scholar · View at Scopus
  44. S. A. Poulsen and R. J. Quinn, “Synthesis and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: potent and selective adenosine A1 receptor antagonists,” Journal of Medicinal Chemistry, vol. 39, no. 21, pp. 4156–4161, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. R. J. Gillespie, I. A. Cliffe, C. E. Dawson et al., “Antagonists of the human adenosine A2A receptor. Part 3: design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 9, pp. 2924–2929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Taliani, C. La Motta, L. Mugnaini et al., “Novel N -Substituted pyrazolo[3,4- d]pyrimidine adenosine A receptor antagonists: inhibition of A-Mediated human glioblastoma cell proliferation,” Journal of Medicinal Chemistry, vol. 53, no. 10, pp. 3954–3963, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Akahane, H. Katayama, T. Mitsunaga et al., “Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonist,” Bioorganic and Medicinal Chemistry Letters, vol. 6, no. 17, pp. 2059–2062, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Akahane, H. Katayama, T. Mitsunaga et al., “Discovery of 6-oxo-3 (2-phenylpyrazolo[1,5-a]pyridin-3-yl) 1(6H)-pyridazinebutanoic acid (FK 838): a novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity,” Journal of Medicinal Chemistry, vol. 42, no. 5, pp. 779–783, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Kuroda, A. Akahane, H. Itani et al., “Discovery of FR166124, a novel water-soluble pyrazolo[1,5-a]pyridine adenosine A1 receptor antagonist,” Bioorganic and Medicinal Chemistry Letters, vol. 9, no. 14, pp. 1979–1984, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. B. B. Fredholm, K. Lindström, S. Dionisotti, and E. Ongini, “[3H]SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies,” Journal of Neurochemistry, vol. 70, no. 3, pp. 1210–1216, 1998. View at Google Scholar · View at Scopus
  51. M. El Yacoubi, C. Ledent, M. Parmentier, E. Ongini, J. Costentin, and J. M. Vaugeois, “In vivo labelling of the adenosine A2A receptor in mouse brain using the selective antagonist [3H]SCH 58261,” European Journal of Neuroscience, vol. 14, no. 9, pp. 1567–1570, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. P. G. Baraldi, B. Cacciari, G. Spalluto et al., “Novel N6-(substituted-phenylcarbamoyl)adenosine-5-uronamides as potent agonists for A3 adenosine receptors,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 802–806, 1996. View at Google Scholar · View at Scopus
  53. P. G. Baraldi, B. Cacciari, M. J. P. De Las Infantas et al., “Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5-N-ethyluronamide as A1 and A3 adenosine receptor agonists,” Journal of Medicinal Chemistry, vol. 41, no. 17, pp. 3174–3185, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Gessi, K. Varani, S. Merighi et al., “Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells,” British Journal of Pharmacology, vol. 134, no. 1, pp. 116–126, 2001. View at Google Scholar · View at Scopus
  55. S. Gessi, K. Varani, S. Merighi et al., “A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study,” Molecular Pharmacology, vol. 61, no. 2, pp. 415–424, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Novellino, E. Abignente, B. Cosimelli et al., “Design, synthesis and biological evaluation of novel N-alkyl- and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs) as novel A1 adenosine receptor antagonists,” Journal of Medicinal Chemistry, vol. 45, no. 23, pp. 5030–5036, 2002. View at Publisher · View at Google Scholar · View at Scopus